Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
about
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesDecitabine in the treatment of myelodysplastic syndromesDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsEpigenetic Control of Haematopoietic Stem Cell Aging and Its Clinical ImplicationsSpotlight on decitabine for myelodysplastic syndromes in Chinese patientsInfections in myelodysplastic syndromesEpigenetic regulation of hematopoietic stem cell agingEquitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptomeGSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cellsAllogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group studyNCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worseDemethylating Agents in the Treatment of CancerLow-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II reportEpigenetic therapies in MDS and AMLDecitabine in the treatment of myelodysplastic syndromes.Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.Myelodysplastic syndromes in the elderly.The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.Clinical development of demethylating agents in hematologyThe role of azacitidine in the management of myelodysplastic syndromes (MDS).Aberrant DNA methylation in malignant melanomaGemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.Cancer/testis antigens: structural and immunobiological properties.Evolution of decitabine development: accomplishments, ongoing investigations, and future strategiesDemethylating agents in myeloid malignancies.Translational application of epigenetic alterations: ovarian cancer as a model.Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromesDecitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.DNA methylation profiling in nanochannels.Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes?A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndromeContinuous zebularine treatment effectively sustains demethylation in human bladder cancer cellsEpigenetic targets for immune intervention in human malignancies.Epigenetic targets in hematopoietic malignancies.
P2860
Q24622700-2FC3EC6B-997D-4E43-9F92-81FB82BD3EBEQ24641906-6077CD42-325B-42D8-9251-B53665355B88Q26749421-5DA9944C-D955-425C-BAD1-48A19A2556ADQ26774949-48B48937-6A32-44D1-A5F9-70C3C0DAA424Q26778454-51050514-408C-41D2-814C-D698EFBF5510Q26859275-96DFAF8A-CF41-4F5C-83AB-75AEEF5F835AQ27026054-4CCB348C-737B-42B8-8974-0182988067D2Q28475641-1A412FC9-94CE-4D2B-9E28-05BCFF3B4CF5Q28477278-C129823B-0346-425C-8003-B9199D834F43Q30274942-CC419396-8778-4A15-9CE7-32EC67F7135DQ31149399-417D0D0B-7FA4-4450-BFD6-B3F4722791E6Q33390459-3435C98A-A319-45C4-9162-ABB1BF49CEF7Q33393647-5CDF434B-BACC-4234-A654-3E2B08033DA2Q33431466-F8B2099B-D7D6-4589-87F8-15657F14DBB1Q33621141-A9133ED4-CC81-41E5-8E4B-F36DA42DEBD8Q33658203-B80743EB-3488-4ED2-B44A-8CB65902ADDAQ33678040-AF81B815-7866-41B9-9394-0F8816549942Q33744733-1299771C-9F16-4EF1-A2C2-73A2969CCF6AQ33863567-57E4F8E4-D04B-4C5F-A8A9-63807EF71924Q34088403-A9FA084F-D57B-496F-802A-70E2955860AFQ34088756-21069C69-E5A9-48B0-9588-EB84737D08F9Q34139758-CFE875C0-A174-49D2-974E-47FACDA4DBB4Q34318060-1D649A5E-7187-4A72-8843-FA52C2FD08F5Q34395179-D14D39F4-3AD6-4484-831A-B278CF9A827EQ34418429-E6915ABF-04F5-4CCC-90EF-EFFBA9337231Q34516587-A92D17C7-76CE-477A-A447-963A252EACF0Q34557714-8567B5F7-BB0D-4F73-B186-C42FBFE2434EQ34568997-3FD18B64-78A2-4BB0-AE5C-4D4006DD8CBCQ34768789-6FF84A5E-BEF5-4876-935C-6C9C7FF47396Q34847863-602A098D-482D-4B9E-8C0B-B708C8BB6AC5Q35085782-CCA07D85-8F10-49DE-9949-04A38DBB39E9Q35087659-1F684896-2D92-4267-9324-90F9129C1138Q35109281-CD0915B1-43AF-4741-BE0E-42570B4D79CCQ35164242-A31E1738-14F9-4933-BA3C-FDEB7C4F8079Q35180494-605C4867-240C-4B9E-9A60-53CBD30A736BQ35217405-BD4B28E2-CE57-42C8-AF06-04F29E966D66Q35265834-398AB3F5-3C5C-4D5A-8A2E-6D6B6C972579Q35545116-7655BE8A-B8B5-4449-9667-381CA977D2ECQ35551107-E2FD5675-D376-4DC1-B615-40A41E528E28Q35551110-39C7BEF7-465E-4214-B2D4-3A18082C26E7
P2860
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Low-dose 5-aza-2'-deoxycytidin ...... II study in elderly patients.
@ast
Low-dose 5-aza-2'-deoxycytidin ...... II study in elderly patients.
@en
type
label
Low-dose 5-aza-2'-deoxycytidin ...... II study in elderly patients.
@ast
Low-dose 5-aza-2'-deoxycytidin ...... II study in elderly patients.
@en
prefLabel
Low-dose 5-aza-2'-deoxycytidin ...... II study in elderly patients.
@ast
Low-dose 5-aza-2'-deoxycytidin ...... II study in elderly patients.
@en
P2093
P1476
Low-dose 5-aza-2'-deoxycytidin ...... II study in elderly patients.
@en
P2093
P Wijermans
P304
P356
10.1200/JCO.2000.18.5.956
P407
P577
2000-03-01T00:00:00Z